Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US44486Q1031
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00XPPT7S7
HUMA
Humacyte Inc
GICS: Financials · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $BANK
NAME
Humacyte Inc
ISIN
US44486Q1031
TICKER
HUMA
MIC
XNAS
REUTERS
HUMA.OQ
BLOOMBERG
HUMA US
Sat, 25.04.2026       Humacyte
US44486Q1031

NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) ("Humacyte" or the "Company")....
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 24.04.2026       Humacyte
US44486Q1031

- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - ...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 22.04.2026       Humacyte
US44486Q1031

– Industry veteran with more than 25 years of experience will lead next phase of biotech company’s commercial expansion –...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.04.2026       Humacyte
US44486Q1031

- The Ministry of Health has set a 180-working-day review period for the MAA - ...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.04.2026       Humacyte
US44486Q1031

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Humacyte, Inc. (NasdaqGS: HUMA) (“Humacyte” or the “Company”). On August 9, 2024, the company announced that the Food and Drug Administration (“FDA”) “will requi...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Humacyte
US44486Q1031

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.Shareholders should contact the firm immediately as there may be limited time to enforce you...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 27.03.2026       Humacyte
US44486Q1031

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year - ...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Humacyte
US44486Q1031

- Mr. McElheney brings more than 15 of years’ experience in corporate development and alliance management at biopharma companies. - ...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Humacyte
US44486Q1031

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Humacyte
US44486Q1031

- Purchase commitment is for a minimum of $1.475 million of Symvess product - - Purchase commitment is for a minimum of $1.475 million of Symvess product -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Thu, 19.03.2026       Humacyte
US44486Q1031

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 02.03.2026       Humacyte
US44486Q1031

DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company’s management team will be participating in the following investor conferences during the month of Ma...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.02.2026       Humacyte
US44486Q1031

DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to su...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.12.2025       Humacyte
US44486Q1031

- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - ...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 16.12.2025       Humacyte
US44486Q1031

DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital G...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.11.2025       Humacyte
US44486Q1031

- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - ...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.10.2025       Humacyte
US44486Q1031

NEW YORK CITY, NEW YORK / ACCESS Newswire / October 14, 2025 / On October 7, 2025, Humacyte, Inc. (Nasdaq:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced that it entered into a securities purchase agreement with certain fundamental institutional...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.10.2025       Humacyte
US44486Q1031

- Results published in Oxford Academic’s Military Medicine Journal -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 18.09.2025       Humacyte
US44486Q1031

- Results were published in JACC: Basic to Translational Science -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 15.09.2025       Humacyte
US44486Q1031

- Results were published in the Journal of Vascular Surgery -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 11.08.2025       Humacyte
US44486Q1031

- Total revenues of $301,000 for quarter, and $818,000 for first six months of 2025, from sales and collaborative research agreement -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.06.2025       Humacyte
US44486Q1031

Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Disease Observed in Data Presented in Plenary Session Benefits of Humacyte’s Acellular Tissue Engineered Vessel Over Autologous Arteriovenous Fistula (AVF) in High-Risk Patients with End-Stage Kidney Dise...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 19.05.2025       Humacyte
US44486Q1031

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will present at the H.C. Wainwright...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 13.05.2025       Humacyte
US44486Q1031

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 09.05.2025       Humacyte
US44486Q1031

DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended March 31, 2025, on Tuesday, May 13, 2025. Management will host a webcast and conf...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 28.03.2025       Humacyte
US44486Q1031

- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma -...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 26.03.2025       Humacyte
US44486Q1031

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public offering price of...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 10.03.2025       Humacyte
US44486Q1031

– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair –...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 06.03.2025       Humacyte
US44486Q1031

Trestle Biotherapeutics, Inc., today announced a research collaboration with Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Trestle Bio is a preclinical stage company developing bioengineered kidney tissues for patients suffering f...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 21.01.2025       Humacyte
US44486Q1031

– Plans for filing an IND was agreed with the FDA in a recent meeting –...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Humacyte
US44486Q1031

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Invest...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Humacyte
US44486Q1031

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024. Humacyte describes itself as a company that “engages in the development and manufacture of off-the-shelf, implantable, and bio...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 17.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Humacyte, Inc. ("HUMA" or "the Company") (NASDAQ: HUMA) for violations of the federal securities laws. Shareholders wh...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 16, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 16.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to con...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.01.2025       Humacyte
US44486Q1031

The Law Offices of Frank R. Cruz reminds investors of the upcoming January 17, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Clas...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.01.2025       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 15.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are enco...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.01.2025       Humacyte
US44486Q1031

BENSALEM, Pa., Jan. 14, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HUMACYTE, INC. (HUMA), CONTACT THE L...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 14.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 13, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 13, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA) have opportunity to lead the securities fraud class action lawsuit....
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Mon, 13.01.2025       Humacyte
US44486Q1031

LOS ANGELES, Jan. 13, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Fri, 10.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to cont...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encou...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.01.2025       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.01.2025       Humacyte
US44486Q1031

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to r...
Read more
Humacyte
Technical Analysis Termsheets Terminal
Permalink